Journal of Renal Nutrition
Volume 18, Issue 4 , Pages 383-388 , July 2008

Use of Cinacalcet HCl to Achieve the Recommended Targets of Bone Metabolism in a Patient With Therapy-Resistant Renal Hyperparathyroidism

  • Udo Bahner, PhD, MD

      Affiliations

    • KfH-Nierenzentrum Wuerzburg, Dialysis Unit, Würzburg, Germany
    • Corresponding Author InformationAddress reprint requests to Udo Bahner, PhD, MD, KfH-Nierenzentrum Wuerzburg, Dialysis Unit, 97080 Würzburg, Germany.
    • ,
  • Margit Brandl, MD

      Affiliations

    • KfH-Nierenzentrum Wuerzburg, Dialysis Unit, Würzburg, Germany
    • ,
  • Christoph Nies, PhD, MD

      Affiliations

    • Marienhospital, Osnabrueck, Germany
    • ,
  • Heinrich Schmidt-Gayk, PhD, MD

      Affiliations

    • Department of Osteology, Laboratory Limbach, Heidelberg, Germany

References 

  1. Hoerl WH. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant. 2004;19(Suppl 5):V2–V8
  2. Henry JF, Denizot A, Audiffret J, et al. Results of reoperation for persistent or recurrent secondary hyperparathyroidism in hemodialysis patients. World J Surg. 1990;14:303–306
  3. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131–2138
  4. Blacher J, Guerin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38:939–942
  5. Strozecki P, Adamowicz A, Nartowicz E, et al. Parathormone, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients. Ren Fail. 2001;23:115–126
  6. Brown EM, Hebert SC. Calcium-receptor-regulated parathyroid and renal function. Bone. 1997;20:303–309
  7. Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol. 2003;14:575–583
  8. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350:1516–1525
  9. Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. Semin Dial. 2005;16:800–807
  10. National Kidney Foundation . K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Kidney Disease Outcomes Quality Initiative. Am J Kidney Dis. 2003;42(Suppl 3):S1–S201
  11. Schlosser K, Sitter H, Rothmund M, et al. Assessing the site of recurrence in patients with secondary hyperparathyroidism by a simplified Casanova autograftectomy test. World J Surg. 2004;28:583–588
  12. Bradwell AR, Harvey TC. Control of hypercalcaemia of parathyroid carcinoma by immunisation. Lancet. 1999;353:370–373
  13. Betea D, Bradwell AR, Harvey TC, et al. Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J Clin Endocrinol Metab. 2004;89:3413–3420
  14. Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 2005;67:760–771
  15. Moe SM, Cunningham J, Bommer J, et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant. 2005;20:2186–2193
  16. Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68:1793–1800
  17. Colloton M, Shatzen E, Miller G, et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int. 2005;67:467–476
  18. Cuppari L, de Carvalho AB, Avesani CM, et al. Increased resting energy expenditure in hemodialysis patients with severe hyperparathyroidism. J Am Soc Nephrol. 2004;15:2933–2939

 We regret to report that Prof. Dr. Med. Heinrich Schmidt-Gayk died on September 18, 2007.

PII: S1051-2276(08)00312-9

doi: 10.1053/j.jrn.2008.05.001

Journal of Renal Nutrition
Volume 18, Issue 4 , Pages 383-388 , July 2008

Article Tools

* Image Usage & Resolution